Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 38,47 € (+23,10%). La mediana è 37,89 € (+21,25%).
| Acquista |
22 |
| Mantieni |
20 |
| Vendi |
4 |
Notizie Vai al feed delle notizie
S&P upgrades Teva to BBB- after debt reduction and strong branded pipeline
S&P Global Ratings has upgraded Teva from BB+ to BBB- and raised all of the company’s ratings. The agency cites ongoing debt reduction, stabilization in the generics business and growth of high-margin branded products; leverage is expected to fall from about 4x in the second quarter to the mid-3x range by year-end. S&P expects strong adjusted operating cash flow of $2.3–2.5 billion annually, substantial cost savings through 2027, as well as revenue gains from key brands such as Austedo, Ajovy and Uzedy and important product launches in the coming years. » Altro su de.investing.com
Teva asks judge to bar mention of Israeli origin at Humana price-fixing trial
Teva asked a U.S. judge to prevent insurer Humana from telling jurors the company is Israeli, arguing references to its national origin could prejudice the jury amid strong U.S. emotions over the Gaza war. The Tel Aviv-based drugmaker said national origin is irrelevant to allegations it conspired to inflate generic drug prices and could undermine a fair trial. The U.S. trial is scheduled to begin Sept. 15 and covers claims over drugs including baclofen and propranolol. » Altro su finance.yahoo.com
Teva Pharmaceutical jumps after Q2 revenue beat and plan for direct NYSE listing
Teva Pharmaceutical shares rose about 12% after its Q2 report where adjusted EPS missed estimates at $0.02 but revenue of $4.1 billion topped consensus and the revenue decline was milder than expected. The company reiterated full-year sales and adjusted EPS guidance slightly below analyst averages and said it will replace ADRs with newly listed common stock on the New York Stock Exchange, starting September 14. Investors welcomed the direct listing as a potential catalyst to attract institutional and retail demand. » Altro su finance.yahoo.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giugno 2026 | |
|---|---|---|
| Ricavi | 3,63 Mld | 2,43% |
| Utile lordo | 1,89 Mld | 5,78% |
| Utile netto | -504,7 Mln | 310,95% |
| EBITDA | -16,65 Mln | 102,99% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 36,47 Mld € |
Numero di azioni | 1,16 Mld |
Massimo/minimo a 52 settimane | 33,04 € - 15,68 € |
| Dividendi | No |
Beta | 0,87 |
Rapporto P/E | 57,81 |
Rapporto PEG | 0,11 |
Rapporto P/B | 5,47 |
Rapporto P/S | 2,44 |
Profilo aziendale
Teva Pharmaceutical Industries Limited, ein Pharmaunternehmen, entwickelt, produziert, vermarktet und vertreibt Generika, Spezialmedikamente und biopharmazeutische Produkte in Nordamerika, Europa und international. Das Unternehmen bietet sterile Produkte, Hormone, hochwirksame Medikamente und zytotoxische Substanzen in verschiedenen Darreichungsformen an, darunter Tabletten, Kapseln, Injektionsmittel, Inhalationsmittel, Flüssigkeiten, transdermale Pflaster, Salben und Cremes. Außerdem entwickelt, produziert und vertreibt das Unternehmen pharmazeutische Wirkstoffe. Darüber hinaus konzentriert sich das Unternehmen auf die Bereiche zentrales Nervensystem, Schmerzen, Atemwege und Onkologie. Zu den Produkten im Bereich des zentralen Nervensystems gehören Copaxone zur Behandlung schubförmiger Formen der Multiplen Sklerose, AJOVY zur vorbeugenden Behandlung von Migräne und AUSTEDO zur Behandlung von Spätdyskinesien und Chorea im Zusammenhang mit der Huntington-Krankheit. Die Produkte des Unternehmens auf dem Atemwegsmarkt umfassen ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler und ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax und AirDuo RespiClick/ArmonAir RespiClick für die Behandlung von Asthma und chronisch obstruktiven Lungenerkrankungen. Zu seinen Produkten auf dem Onkologiemarkt gehören Bendeka, Treanda, Granix, Trisenox, Lonquex und Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited kooperiert mit MedinCell bei der Entwicklung und Vermarktung mehrerer langwirksamer injizierbarer Produkte, einer Risperidon-Suspension für die Behandlung von Patienten mit Schizophrenie. Das Unternehmen wurde 1901 gegründet und hat seinen Hauptsitz in Tel Aviv-Yafo, Israel.
| Nome | Teva Pharmaceuticals |
| CEO | Richard D. Francis |
| Sede centrale | Tel Aviv,
ta Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 16/02/1982 |
| Dipendenti | 32.008 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | TEVA |
Frankfurt | TEV.F |
Düsseldorf | TEV.DU |
Hamburg | TEV.HM |
London | 0LER.L |
SIX | TEVA.SW |
München | TEV.MU |
Wien | TEVA.VI |
Scopri gli asset
Gli azionisti di Teva Pharmaceuticals investono anche nei seguenti asset